Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by ScienceFirston Apr 08, 2022 11:39am
247 Views
Post# 34588024

Breakthrough designation ahead of AUA congress

Breakthrough designation ahead of AUA congressImagine receiving a FDA Breakthrough designation by the FDA before the AUA annual meeting!  That would certainly give us huge visibilitity.

Hopefully, they submitted the Nov. 29 data for a late-breaking abstract.

AUA congress is May 13-16.

the American Urological Association's 2022 Annual Meeting, May 13 - 16, 2022 in New Orleans.


AUA2022 Key Dates

Friday, June 25, 2021

Course Application Deadline

Monday, August 2, 2021

Abstract Submission Site Opens

Monday, November 1, 2021

Paper and Video Abstract Submission Site Closes

Tuesday, December 14, 2021

Registration Opens

Monday, January 3, 2022

Late-breaking Abstract Submission Site Opens

Friday, January 7, 2022

Abstract Notifications Sent

Tuesday, January 18, 2022

Group Registration Opens

Tuesday, January 18, 2022

Exhibitor Registration Opens

Monday, February 14, 2022

Late-breaking Abstract Submission Site Closes

Tuesday, March 22, 2022

Early-Bird Registration Deadline

Tuesday, March 22, 2022

Course Registration Discount Deadline

Friday, May 13, 2022

Annual Meeting Begins

Monday, May 16, 2022

Annual Meetin


<< Previous
Bullboard Posts
Next >>